美国

证券交易委员会

华盛顿特区，20549

表格8-K

当前报告

根据 1934年证券交易法 第13或15（d）条

报告日期(最早报告事件日期)： 2024年3月4日

AKARI 治疗，PLC

(注册人在其章程中规定的确切名称 )

注册人的电话号码，包括区号：（929） 274—7510

不适用
(前姓名或前地址，如果自上次报告后更改)

如果申请表8-K 旨在同时满足注册人根据下列任何一项规定的备案义务，请勾选下面相应的框：

根据该法第12(B)款登记的证券：

*交易，但仅限于与美国存托股份(美国存托股份)相关的交易。

用复选标记表示注册人 是否是1933年《证券法》规则第405条(本章230.405节)或1934年《证券交易法》规则第12b-2条(本章第240.12b-2节)所界定的新兴成长型公司。

新兴的成长型公司？

如果 是一家新兴成长型公司，请用复选标记表示注册人是否已选择不使用延长的过渡期来遵守根据《交易所法案》第13(A)节提供的任何新的或修订的财务会计准则。？

合并协议

2024年3月4日，Akari治疗公司(一家在英格兰和威尔士注册成立的上市公司)与Peak Bio，Inc.(“Peak Bio”)和Pegasus Merger Sub，Inc.，特拉华州一家公司和Akari的全资子公司(“Merge Sub”)签订了一项合并协议和计划(“合并协议”)，根据协议的条款和条件，合并子公司将与Peak Bio，Inc.(“合并”)合并。Peak Bio作为Akari的全资子公司在合并后存活了下来。

根据合并协议，并根据 条款及受制于该等条件，于合并生效时(“生效时间”)，各发行 及已发行的公司普通股，每股面值0.0001美元(“匹克普通股”)(不包括(X)股匹克生物作为库存股持有的匹克普通股股份，或由Akari、合并子公司或任何直接或间接全资附属公司拥有的匹克普通股股份，及(Y)股异议股份(定义见合并协议)，将转换为权利 以收取相当于若干Akari普通股的Akari美国存托股份(“Akari ADS”)，面值为每股0.0001美元(“Akari普通股”)，相当于根据合并 协议计算的交换比率(“交换比率”)，根据存款协议(定义见合并协议)缴存所需数目的Akari普通股而正式及有效发行的每股该等股份。交换比率将按交换比率计算 ，以作为匹克普通股的合并代价而发行的Akari ADS股份总数预计于发行时约为Akari ADS已发行股份的50%(前提是该比率将就Akari及Peak Bio各自于预期完成合并前一个营业日的营业时间结束时根据合并协议厘定的现金净值作出若干调整)。合并协议规定，在某些情况下，在合并完成后，可向匹克普通股的股份持有人额外发行 张美国存托凭证，相当于根据合并协议计算的 交换比率(“额外交换比率”)。

于生效时间，每份购买Peak Bio股本的权证(“Peak认股权证”)将于紧接生效时间前转换为 ，并可交换为由Akari厘定的购买若干Akari普通股或Akari ADS的认股权证(每个为“经调整 认股权证”)，其条款及条件与紧接生效时间前适用于该等峰值认股权证的条款及条件大致相若，但(I)因合并协议拟进行的交易而无法生效的条款除外，(Ii)如以下句子所述及(Iii)根据适用法律(定义见合并协议)对经调整认股权证的条款作出必要的修订。受每份调整认股权证约束的Akari普通股(或Akari ADS相关的Akari普通股数量 )将等于紧接生效时间前该峰值认股权证行使时可发行的峰值普通股数量乘以兑换比率， 任何零碎的Akari普通股或Akari ADS向下舍入为最接近的完整Akari普通股或Akari美国存托股份(视情况而定)， 以及每股Akari普通股(或每股Akari相关ADS，如适用) 相关经调整认股权证将等于紧接生效时间前该等峰值认股权证的行使价除以兑换比率。经调整认股权证的授出将自生效时间起生效，或在考虑到母公司的行政程序后，在合理可行的情况下尽快生效。经调整认股权证将进一步调整(如适用) ，以落实额外兑换比率的影响。

收购匹克普通股 股票的每一项期权(“匹克期权”)在紧接生效时间之前尚未行使且未行使，无论是否已归属，都将被假定并转换为购买若干Akari普通股或Akari美国存托凭证的期权，由Akari 决定(每个，“调整后期权”)。受调整后期权约束的阿卡里普通股数量(或相关的阿卡里普通股数量，视情况而定)将等于(I)在紧接生效时间之前受该峰值期权约束的普通股总数乘以(Ii)兑换比率，任何 分数的阿卡里普通股或阿卡里美国存托凭证向下舍入为最接近的完整阿卡里普通股或阿卡里美国存托股份(视情况适用)的乘积。和 每股经调整期权的行权价将等于紧接生效时间之前该Peak期权的行权价除以兑换比率。调整后的期权将进一步调整(如果适用)，以实现额外汇率比率的影响 。

合并协议包含由Akari、Peak Bio和Merger Sub提供的惯例陈述、 担保和契诺。合并协议还包含惯例的成交前契约， 包括双方在合并完成前各自开展各自业务的契约。此外，各方已同意利用各自在商业上合理的努力，采取一切必要、适当或可取的行动来完成合并和合并协议预期的其他交易，包括在合理可行的情况下尽快就合并提交任何所需的监管备案文件，但Akari和Peak Bio均不需要剥离Peak Bio的任何资产或业务。Akari或其各自的任何附属公司和子公司。

合并协议 还规定，从合并生效时间和合并协议终止之日起，Akari和Peak生物各自在向第三方征求收购建议、向第三方提供信息以及与第三方就收购建议进行讨论的能力方面受到某些限制，但符合惯例的例外情况除外。此外， Akari和Peak Bio的董事会都必须建议各自的股东或股东投票赞成合并，但有更高提议的例外情况和其他未能实施建议变更的情况 将与董事会的受托责任不一致。

合并的完成取决于各种 条件，其中包括：(I)Peak Bio股东批准合并协议和合并，(Ii)Akari的股东授权Akari董事会分配与合并相关的所有Akari普通股 (由Akari ADS代表)，(Iii)没有任何禁止完成合并的法律或命令，(Iv)Akari采用S-4表格的注册声明(将与合并相关发布)已宣布生效，(V)可发行给匹克生物股东的美国存托凭证已获授权在纳斯达克上市，(Vi)另一方陈述和担保的准确性(受合并协议中规定的某些重大标准的约束)，(Vii)另一方在所有实质性方面遵守该另一方在合并协议下的义务的情况。(Viii)在没有对另一方造成重大不利影响的情况下，(Ix)另一方的现金净值大于负13,500,000美元，以及(X)根据合并协议的定义，管道投资(Br)应在交易完成时同时完成，且仅以此为条件，并应为Akari带来至少10,000,000美元的净收益。

在某些情况下，阿卡里或匹克生物可终止合并协议 如果(I)合并未于2024年9月4日前完成，(Ii)另一方董事会撤回、修改或修改其建议，以支持合并协议所设想的交易，或批准或建议替代交易，或(Iii)阿卡里或匹克生物董事会， 根据适用情况，决定在获得阿卡里 美国存托股份发行或合并批准之前，就更高提议达成最终协议，从Akari的股东或Peak Bio的股东(视情况而定)。合并协议 还规定，在合并协议、Akari或Peak Bio(视情况而定)所述的特定终止情况下， 将被要求支付相当于300,000美元的终止费，并向另一方偿还与交易相关的费用，最高可达 150万美元。

其他 信息

以上是对合并和合并协议的一般描述；它并不声称是完整的，并通过参考合并协议进行了整体限定， 该合并协议作为本8-K表格的附件2.1附于本报告，并通过引用并入本文。

The Merger Agreement, which is attached as Exhibit 2.1, has been described above to provide investors and Akari shareholders with information regarding the terms of the Merger Agreement and is not intended to modify or supplement any factual disclosures about Akari, Merger Sub or Peak Bio or any of their respective affiliates. The representations, warranties and covenants contained in the Merger Agreement were made only for the purposes of the Merger Agreement, were made as of specific dates, were made solely for the benefit of the parties to the Merger Agreement and may not have been intended to be statements of fact, but rather, as a method of allocating risk and governing the contractual rights and relationships among the parties to the Merger Agreement. In addition, such representations, warranties and covenants may have been qualified by certain disclosures not reflected in the text of the Merger Agreement and may apply standards of materiality and other qualifications and limitations in a way that is different from what may be viewed as material by Akari’s shareholders or Peak Bio’s stockholders. In reviewing the representations, warranties and covenants contained in the Merger Agreement or any descriptions thereof in this summary, it is important to bear in mind that such representations, warranties and covenants or any descriptions were not intended by the parties to the Merger Agreement to be characterizations of the actual state of facts or conditions of Akari, Merger Sub or Peak Bio or any of their respective affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in public disclosures. For the foregoing reasons, the representations, warranties and covenants or any descriptions of those provisions should not be read alone and should instead be read in conjunction with the other information contained in the reports, statements and filings that Akari and Peak Bio publicly file with the SEC.

投票协议

与 合并协议同时，Akari和Peak Bio与Akari的某些 股东（“Akari股东”）和Peak Bio的某些股东（“Peak股东” ，以及Akari股东一起称为“支持股东”）订立了投票和支持协议（“投票协议”）。支持持有人已同意（其中包括）根据Akari和Peak Bio各自董事会的建议，投票支持合并协议和合并或发行Akari普通股（如适用）。

截至2024年3月1日，Akari股东实益拥有合计约39.51%的已发行Akari普通股。截至 二零二四年三月一日，Peak股东实益拥有Peak普通股 合共约39. 3%的已发行股份。

投票协议 将于（a）生效时间、（b）收到支持持有人的批准（如适用）以及（c）合并协议有效终止的日期和时间（以最早日期为准）终止。

上述表决协议 的描述并不完整，而是受表决协议形式的约束，并受表决协议形式的全部限制， 的形式作为附件10.1和10.2提交，并通过引用并入本文。

2024年3月5日，Akari和Peak Bio发布联合新闻稿，宣布执行合并协议。新闻稿作为附件99.1附于本协议。

根据本第7.01项（ 包括附件99.1）提供的信息不应被视为根据1934年《证券交易法》第18条（ 修订）的目的“已提交（《交易法》），或以其他方式受该条下的法律责任约束，且不得视为 以引用的方式纳入根据1933年证券法或交易法提交的任何文件中，除非在此类文件中以特定的引用方式明确规定。此外，附件99.1包含旨在作为"前瞻性陈述"的陈述， 受此类附件中所列前瞻性陈述的警示性陈述的约束。

(D)展品。

首席执行官

This current report relates to the proposed transaction pursuant to the terms of the Merger Agreement, by and among Akari, Pegasus Merger Sub, Inc., and Peak Bio and includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act, about the proposed transaction between Peak Bio and Akari and the operations of the combined company that involve risks and uncertainties relating to future events and the future performance of Akari and Peak Bio. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding: the Merger and related matters, including, but not limited to, satisfaction of closing conditions to the proposed transaction, prospective performance and opportunities with respect to Akari or Peak Bio, post-closing operations and the outlook for the companies’ businesses; Akari’s, Peak Bio’s or the combined company’s targets, plans, objectives or goals for future operations, including those related to Akari’s and Peak Bio’s product candidates, research and development, product candidate introductions and product candidate approvals as well as cooperation in relation thereto; projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures; future economic performance, future actions and outcome of contingencies such as legal proceedings; and the assumptions underlying or relating to such statements.

These statements are based on Akari’s and Peak Bio’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: uncertainties as to the timing for completion of the proposed transaction; uncertainties as to Peak Bio’s and/or Akari’s ability to obtain the approval of Akari’s shareholders or Peak Bio’s stockholders required to consummate the proposed transaction; the possibility that competing offers will be made by third parties; the occurrence of events that may give rise to a right of one or both of Akari and Peak Bio to terminate the Merger Agreement; the possibility that various closing conditions for the proposed transaction may not be satisfied or waived on a timely basis or at all, including the possibility that a governmental entity may prohibit, delay, or refuse to grant approval, if required, for the consummation of the proposed transaction (or only grant approval subject to adverse conditions or limitations); the difficulty of predicting the timing or outcome of consents or regulatory approvals or actions, if any; the possibility that the proposed transaction may not be completed in the time frame expected by Akari and Peak Bio, or at all; the risk that Akari and Peak Bio may not realize the anticipated benefits of the proposed transaction in the time frame expected, or at all; the effects of the proposed transaction on relationships with Akari’s or Peak Bio’s employees, business or collaboration partners or governmental entities; the ability to retain and hire key personnel; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction; significant or unexpected costs, charges or expenses resulting from the proposed transaction; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the combined business after the consummation of the proposed transaction; potential negative effects related to this announcement or the consummation of the proposed transaction on the market price of Akari’s American Depositary Shares or Peak Bio’s common stock and/or Akari’s or Peak Bio’s operating or financial results; uncertainties as to the long-term value of Akari’s American Depositary Shares (and the ordinary shares represented thereby), including the dilution caused by Akari’s issuance of additional American Depositary Shares (and the ordinary shares represented thereby) in connection with the proposed transaction; unknown liabilities related to Akari or Peak Bio; the nature, cost and outcome of any litigation and other legal proceedings involving Akari, Peak Bio or their respective directors, including any legal proceedings related to the proposed transaction; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of Akari’s or Peak Bio’s programs or product candidates; risks related to any loss of Akari’s or Peak Bio’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for Akari or Peak Bio’s product candidates, the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by Akari, Peak Bio and/or their respective collaborators or licensees; the extent to which the results from the research and development programs conducted by Akari, Peak Bio, and/or their respective collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of Akari’s or Peak Bio’s product candidates, and the impact of studies (whether conducted by Akari, Peak Bio or others and whether mandated or voluntary) on any of the foregoing; unexpected breaches or terminations with respect to Akari’s or Peak Bios’s material contracts or arrangements; risks related to competition for Akari’s or Peak Bio’s product candidates; Akari’s or Peak Bio’s ability to successfully develop or commercialize Akari’s or Peak Bio’s product candidates; Akari’s, Peak Bio’s, and their collaborators’ abilities to continue to conduct current and future developmental, preclinical and clinical programs; potential exposure to legal proceedings and investigations; risks related to changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing, development or commercialization of any of Akari’s or Peak Bio’s product candidates; unexpected increase in costs and expenses with respect to the potential transaction or Akari’s or Peak Bio’s business or operations; and risks and uncertainties related to epidemics, pandemics or other public health crises and their impact on Akari’s and Peak Bio’s respective businesses, operations, supply chain, patient enrollment and retention, preclinical and clinical trials, strategy, goals and anticipated milestones. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. There can be no assurance that the proposed transaction or any other transaction described above will in fact be consummated in the manner described or at all. A more complete description of these and other material risks can be found in Akari’s and Peak Bios’s respective filings with the U.S. Securities and Exchange Commission (the “SEC”), including each of their Annual Reports on Form 20-F and 10-K, respectively, for the year ended December 31, 2022, subsequent periodic reports, and other documents that may be filed from time to time with the SEC. These risks, as well as other risks associated with the proposed transaction, will be more fully discussed in the joint proxy statement/prospectus that will be included in the registration statement on Form S-4 that will be filed with the SEC in connection with the proposed transaction, which joint proxy statement/prospectus will be mailed or otherwise disseminated to Akari’s shareholders and Peak Bio’s stockholders when it becomes available.

Any forward-looking statements speak only as of the date of this communication and are made based on the current beliefs and judgments of Akari’s and Peak Bio’s management, and the reader is cautioned not to rely on any forward-looking statements made by Akari or Peak Bio. Unless required by law, neither Akari nor Peak Bio is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this document, including without limitation any financial projection or guidance, whether as a result of new information, future events or otherwise.

No Offer or Solicitation

This current report is not intended to and shall not constitute an offer to subscribe for, buy or sell or the solicitation of an offer to subscribe for, buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of, or offer to sell or buy, securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This communication is for informational purposes only. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Additional Information and Where to Find It

In connection with the proposed transaction, Akari and Peak Bio expect to file with the SEC a Registration Statement on Form S-4. The Registration Statement on Form S-4 will include a prospectus of Akari and a joint proxy statement of Akari and Peak Bio, and each party may also file other documents regarding the proposed transaction with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY THE REGISTRATION STATEMENT ON FORM S-4, JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN, IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION, RELATED MATTERS AND THE PARTIES TO THE PROPOSED TRANSACTION.

You may obtain a free copy of the Registration Statement on Form S-4, joint proxy statement/prospectus and other relevant documents (if and when they become available) that are or will be filed with the SEC for free at the SEC’s website at www.sec.gov. Copies of the documents filed with the SEC by Akari will be available free of charge on Akari’s website at http://investor.akaritx.com/ or by contacting Akari’s Investor Relations Department at http://investor.akaritx.com/investor-resources/contact-us. Copies of the documents filed with the SEC by Peak Bio will be available free of charge on Peak Bio’s website at https://peak-bio.com/investors or by contacting Peak Bio’s Investor Relations Department at https://peak-bio.com/contact.

Participants in the Solicitation

Akari, Peak Bio and their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about the directors and executive officers of Akari, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in Akari’s Annual Report on Form 20-F for the year ended December 31, 2022 filed with the SEC on May 1, 2023, subsequent quarterly and current reports on Form 10-Q and -K, respectively, and other documents that may be filed from time to time with the SEC. Information about the directors and executive officers of Peak Bio, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in Peak Bio’s proxy statement for its 2022 Special Meeting of Stockholders, which was filed with the SEC on October 19, 2022, the Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on June 29, 2023, subsequent quarterly and current reports on Form 10-Q and Form 8-K, respectively, and other documents that may be filed from time to time with the SEC. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus included in the Registration Statement on Form S-4 and other relevant materials to be filed with the SEC regarding the proposed transaction when such materials become available. Security holders, potential investors and other readers should read the joint proxy statement/prospectus, included in the Registration Statement on Form S-4 carefully when it becomes available before making any voting or investment decision. You may obtain free copies of these documents from Akari or Peak Bio using the sources indicated above.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.